Coreg. Buy more. Save more.

The world’s largest generics company is also expected to be strong in biogenerics. In 2004, Teva purchased Sicor, which markets G-CSF, human growth hormone and interferon alpha in Eastern Europe and emerging markets. Gate, a subsidiary of Teva, sells human growth hormone in the United States as branded Tev-Tropin.
In 2005, Teva acquired Ivax, which is developing generic insulin and human growth hormone.
The company is growing quickly. Net sales for the third quarter of 2006 increased 74 percent to $2.3 billion, compared with $1.3 billion in the third quarter of 2005. The main contributors to the year-over-year growth in sales were several new product launches in the United States, including Simvastatin, Sertraline, Bupropion and Pravastatin, and sales of Ivax products.

Most Popular
5 Regular Mistakes In Public Speaking
3 Questions No Job Seeker Ever Wants To Be Asked?
10 Jobs That Pay $30 An Hour
13 Job Interview Mistakes To Avoid
Today’s Best Part-Time Jobs

Recent product launches for the company include generic Famvir and Coreg tablets.
Mylan is a global pharmaceutical company with market leading positions in generic pharmaceuticals, transdermal technology and unit dose packaged products.
Mylan operates through three principal subsidiaries: Mylan Pharmaceuticals a world leader in generic pharmaceuticals; Mylan Technologies, the largest producer of generic and branded transdermal patches for the U.S. market; and UDL Laboratories, the top U.S. supplier of unit-dose pharmaceuticals.
The company announced its financial results for the first quarter of fiscal 2008, which included adjusted diluted cash earnings per share of $0.52 compared with $0.35 in the first quarter of fiscal 2007. Mylan’s first quarter was a record in terms of both net revenues, which increased by 55.6 percent to $542.7 million compared with $348.8 million in the year-ago quarter, and operating income, up $70.9 million from the year-ago quarter to $188.1 million for the three months ended June 30, 2007. The record net revenues were achieved excluding any contribution from Matrix Laboratories Limited, which was acquired in the fourth quarter of the prior year. Additionally, Matrix’s sales of $91.3 million increased 15 percent over the fourth quarter of fiscal 2007.
A year ago Barr acquired Croatian company Pliva and it’s expected that the company will be strong in developing insulin and human growth hormone. Pliva is developing G-CSF (granulocyte-colony stimulating factor) and has received European approval for generic erythropoietin.
Barr reported net earnings growth for fiscal 2006 of 56.5 percent year-on-year, to reach $336.5 million. This compares with net earnings of $215.0 million in fiscal year 2005.
Generic sales for the Woodcliff Lake, N.J.-based company for fiscal 2006 were $839 million, a 12 percent increase over fiscal 2005, when generics generated revenues of $751 million. The company currently markets 75 generic products in approximately 100 dosage forms and strengths. Its strongest product lines are in oral contraceptives and warfarin sodium. Last year it also launched an authorized generic version of contraceptive Seasonale (levonorgestrel/ethinyl estradioal).
Lupin Pharmaceuticals is the U.S. wholly owned subsidiary of Lupin Limited, which is among the top five pharmaceutical companies in India. Lupin entered the U.S. generic pharmaceutical market in 2003 with the ANDA approval for cefuroxime axetil, the generic of the antibiotic ceftin. Since then, it has received more than a dozen Food and Drug Administration approvals. Six of Lupin’s 14 ANDA approvals were the first granted by the FDA, reinforcing its ability to gain approvals on time.
The company recently received drug approvals for generic Norvasc, Mavik and Geodon.
The company also has received an exclusive license to use the Suprax trademark in the United States. The drug is an anti-infective medication used in pediatric practice.
For the financial year ending March 2006, Lupin’s revenue and profit were $310 million and $41 million respectively.
Sandoz is the generic arm of Novartis, and it has the only product approved as a ‘follow-on’ drug (as opposed to a biogeneric) in the United States. Omnitrope was approved as a biosimilar in Europe, Australia and other countries as a human growth hormone.
According to Sandoz, the company has six biopharmaceutical projects in its pipeline, and expects to file another NDA this year. Last year Sandoz signed exclusive collaboration with Momenta Pharmaceuticals to focus on developing complex generics and follow-on biotechnology drugs
Sandoz reported generic pharmaceutical sales in 2006 of $5.9 billion. Its generics focus on antibiotics, preparations for treating the central nervous system, the gastrointestinal area and cardiovascular system as well as hormones and antiallergics. Last year it launched generic versions of blockbuster drugs Xanax and Zithromax.
There are already several of Wockhardt’s biologic drugs on the Indian market, but the company is expected to partner with drug companies in Europe and the United States when a pathway is created for the approval of biogenerics.
Wockhardt’s revenue for third quarter 2006 increased 22 percent compared with the third quarter 2005 to $99.4 million). This increase was seen both internationally (an increase of 11 percent) and domestically fan increase of 38 percent).